201 related articles for article (PubMed ID: 34689714)
1. Tumour suppressor TET2 safeguards enhancers from aberrant DNA methylation and epigenetic reprogramming in ERα-positive breast cancer cells.
Lyu R; Zhu X; Shen Y; Xiong L; Liu L; Liu H; Wu F; Argueta C; Tan L
Epigenetics; 2022 Oct; 17(10):1180-1194. PubMed ID: 34689714
[TBL] [Abstract][Full Text] [Related]
2. Regulation of TET2 gene expression and 5mC oxidation in breast cancer cells by estrogen signaling.
Zhu X; Xiong L; Lyu R; Shen Y; Liu L; Li S; Argueta C; Tan L
Biochem Biophys Res Commun; 2022 Jan; 589():240-246. PubMed ID: 34929447
[TBL] [Abstract][Full Text] [Related]
3. TET2 coactivates gene expression through demethylation of enhancers.
Wang L; Ozark PA; Smith ER; Zhao Z; Marshall SA; Rendleman EJ; Piunti A; Ryan C; Whelan AL; Helmin KA; Morgan MA; Zou L; Singer BD; Shilatifard A
Sci Adv; 2018 Nov; 4(11):eaau6986. PubMed ID: 30417100
[TBL] [Abstract][Full Text] [Related]
4. High estrogen during ovarian stimulation induced loss of maternal imprinted methylation that is essential for placental development via overexpression of TET2 in mouse oocytes.
Lu X; Mao J; Qian C; Lei H; Mu F; Sun H; Yan S; Fang Z; Lu J; Xu Q; Dong J; Su D; Wang J; Jin N; Chen S; Wang X
Cell Commun Signal; 2024 Feb; 22(1):135. PubMed ID: 38374066
[TBL] [Abstract][Full Text] [Related]
5. TET2 directs mammary luminal cell differentiation and endocrine response.
Kim MR; Wu MJ; Zhang Y; Yang JY; Chang CJ
Nat Commun; 2020 Sep; 11(1):4642. PubMed ID: 32934200
[TBL] [Abstract][Full Text] [Related]
6. TET2 is a component of the estrogen receptor complex and controls 5mC to 5hmC conversion at estrogen receptor cis-regulatory regions.
Broome R; Chernukhin I; Jamieson S; Kishore K; Papachristou EK; Mao SQ; Tejedo CG; Mahtey A; Theodorou V; Groen AJ; D'Santos C; Balasubramanian S; Farcas AM; Siersbæk R; Carroll JS
Cell Rep; 2021 Feb; 34(8):108776. PubMed ID: 33626359
[TBL] [Abstract][Full Text] [Related]
7. 5mC oxidation by Tet2 modulates enhancer activity and timing of transcriptome reprogramming during differentiation.
Hon GC; Song CX; Du T; Jin F; Selvaraj S; Lee AY; Yen CA; Ye Z; Mao SQ; Wang BA; Kuan S; Edsall LE; Zhao BS; Xu GL; He C; Ren B
Mol Cell; 2014 Oct; 56(2):286-297. PubMed ID: 25263596
[TBL] [Abstract][Full Text] [Related]
8. Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis.
Rasmussen KD; Jia G; Johansen JV; Pedersen MT; Rapin N; Bagger FO; Porse BT; Bernard OA; Christensen J; Helin K
Genes Dev; 2015 May; 29(9):910-22. PubMed ID: 25886910
[TBL] [Abstract][Full Text] [Related]
9. A hypermethylation strategy utilized by enhancer-bound CARM1 to promote estrogen receptor α-dependent transcriptional activation and breast carcinogenesis.
Peng BL; Li WJ; Ding JC; He YH; Ran T; Xie BL; Wang ZR; Shen HF; Xiao RQ; Gao WW; Ye TY; Gao X; Liu W
Theranostics; 2020; 10(8):3451-3473. PubMed ID: 32206101
[TBL] [Abstract][Full Text] [Related]
10. TET proteins and 5-methylcytosine oxidation in hematological cancers.
Ko M; An J; Pastor WA; Koralov SB; Rajewsky K; Rao A
Immunol Rev; 2015 Jan; 263(1):6-21. PubMed ID: 25510268
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic silencing of TET2 and TET3 induces an EMT-like process in melanoma.
Gong F; Guo Y; Niu Y; Jin J; Zhang X; Shi X; Zhang L; Li R; Chen L; Ma RZ
Oncotarget; 2017 Jan; 8(1):315-328. PubMed ID: 27852070
[TBL] [Abstract][Full Text] [Related]
12. MYC deregulates TET1 and TET2 expression to control global DNA (hydroxy)methylation and gene expression to maintain a neoplastic phenotype in T-ALL.
Poole CJ; Lodh A; Choi JH; van Riggelen J
Epigenetics Chromatin; 2019 Jul; 12(1):41. PubMed ID: 31266538
[TBL] [Abstract][Full Text] [Related]
13. DNA methylcytosine dioxygenase ten-eleven translocation 2 enhances lipopolysaccharide-induced cytokine expression in human dental pulp cells by regulating MyD88 hydroxymethylation.
Wang X; Feng Z; Li Q; Yi B; Xu Q
Cell Tissue Res; 2018 Aug; 373(2):477-485. PubMed ID: 29654353
[TBL] [Abstract][Full Text] [Related]
14. A Non-canonical Role of YAP/TEAD Is Required for Activation of Estrogen-Regulated Enhancers in Breast Cancer.
Zhu C; Li L; Zhang Z; Bi M; Wang H; Su W; Hernandez K; Liu P; Chen J; Chen M; Huang TH; Chen L; Liu Z
Mol Cell; 2019 Aug; 75(4):791-806.e8. PubMed ID: 31303470
[TBL] [Abstract][Full Text] [Related]
15. TET-mediated DNA demethylation controls gastrulation by regulating Lefty-Nodal signalling.
Dai HQ; Wang BA; Yang L; Chen JJ; Zhu GC; Sun ML; Ge H; Wang R; Chapman DL; Tang F; Sun X; Xu GL
Nature; 2016 Oct; 538(7626):528-532. PubMed ID: 27760115
[TBL] [Abstract][Full Text] [Related]
16. TET2-mediated epigenetic reprogramming of breast cancer cells impairs lysosome biogenesis.
Laurent A; Madigou T; Bizot M; Turpin M; Palierne G; Mahé E; Guimard S; Métivier R; Avner S; Le Péron C; Salbert G
Life Sci Alliance; 2022 Jul; 5(7):. PubMed ID: 35351824
[TBL] [Abstract][Full Text] [Related]
17. Interplay of ERα binding and DNA methylation in the intron-2 determines the expression and estrogen regulation of cystatin A in breast cancer cells.
John Mary DJS; Sikarwar G; Kumar A; Limaye AM
Mol Cell Endocrinol; 2020 Mar; 504():110701. PubMed ID: 31926189
[TBL] [Abstract][Full Text] [Related]
18. The pioneer factor PBX1 is a novel driver of metastatic progression in ERα-positive breast cancer.
Magnani L; Patten DK; Nguyen VT; Hong SP; Steel JH; Patel N; Lombardo Y; Faronato M; Gomes AR; Woodley L; Page K; Guttery D; Primrose L; Fernandez Garcia D; Shaw J; Viola P; Green A; Nolan C; Ellis IO; Rakha EA; Shousha S; Lam EW; Győrffy B; Lupien M; Coombes RC
Oncotarget; 2015 Sep; 6(26):21878-91. PubMed ID: 26215677
[TBL] [Abstract][Full Text] [Related]
19. Early-stage epigenetic modification during somatic cell reprogramming by Parp1 and Tet2.
Doege CA; Inoue K; Yamashita T; Rhee DB; Travis S; Fujita R; Guarnieri P; Bhagat G; Vanti WB; Shih A; Levine RL; Nik S; Chen EI; Abeliovich A
Nature; 2012 Aug; 488(7413):652-5. PubMed ID: 22902501
[TBL] [Abstract][Full Text] [Related]
20. Association of high 5-hydroxymethylcytosine levels with Ten Eleven Translocation 2 overexpression and inflammation in Sjögren's syndrome patients.
Lagos C; Carvajal P; Castro I; Jara D; González S; Aguilera S; Barrera MJ; Quest AFG; Bahamondes V; Molina C; Urzúa U; Hermoso MA; Leyton C; González MJ
Clin Immunol; 2018 Nov; 196():85-96. PubMed ID: 29894742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
